Faeth Therapeutics, Inc (FTH) FinancialsFTHFaeth Therapeutics, Inc

Evaluating the bottom line, Faeth Therapeutics, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.26%, provide a clear picture of how effectively FTH converts its operational activities into shareholder value.

In the context of the broader market, FTH competes directly with industry leaders such as AURA and IVA. With a market capitalization of $732.58M, it holds a significant position in the sector. When comparing efficiency, FTH's gross margin of N/A stands against AURA's N/A and IVA's 100.00%. Such benchmarking helps identify whether Faeth Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

The company has reported increasing net losses, with a Q2 2026 net loss of $16 million, and a current ratio of 19.69 indicating strong liquidity but poor profitability.